Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants, New Report Launched

A Pipeline Landscape Analysis and Comparative Assessment of Key Players:

This report provides an update of recombinant coagulation factors used for controlling bleeding of hemophilia A and B and other bleeding disorders. 2013 sales figures and 2014 nine-month sales data are analyzed to evaluate commercial development of the market under the light of a strong pipeline and entry of new competitor products into the market. The profiles of drug candidates in development are presented in details not only for recombinant coagulation factors VIII, IX and VII, but also for emerging alternative procoagulants, gene therapeutics and immune tolerance inducing agents.

The competitve landscape of classical recombinant coagulation factors and of new emerging treatment modalities of hemophilia and other severe bleeding orders is analyzed. The emergence of new treatment modalities brings many new stakeholders to the field of hemophilia. Among them are the established hemophilia portofolio companies, but also new entrants from Big Pharma and Big Biotech, specialty pharmaceutical companies, biosimilar companies, and new technology providers as half-life prolongation technologies are no longer in the focus of major interest.

A short- to mid-term outlook into the field is provided and the trends driving the future of this therapeutic segment are identified and described. The data are presented, analyzed and assessed in a comprehensive manner by an experienced author with an independent view writing the fifth edition of this report series.

Benefits from the report:

• Development of product sales and recombinant coagulation factors market
• Sales performance of newly launched recombinant coagulation factors
• Drug profiles for all relevant classical as well a semerging developments
• Technologies, constructs and players in the gene therapy field of hemophilia
• Alternative procoagulants: approaches, profiles, competitive advantages
• Comparative analysis of key product features of new coagulation factors
• Corporate profiles of all relevant stakeholders including deals and pipelines
• Pipeline and technology trends

Spanning over 210 pages, “Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants” report covering the Executive Summary, Recombinant Coagulation Factor Markets, Pipeline Update of Recombinant Coagulation Factors, Competitive Landscape Analysis of Recombinant Coagulation Factors, Stakeholder Profiles, Strategic Analysis, References, ADDENDUM: Development and Approval Timelines. The report covered companies are - Alnylam Pharmaceuticals, Alphamab, Alteogen, Amarna Therapeutics, Apitope, Arcturus Therapeutics, Aryogen, AstraZeneca, Baxter, Bayer HealthCare Pharmaceuticals, Biogen Idec, Biotest, Catalyst Biosciences

Know more about this report at – http://mrr.cm/43y

Find all Therapeutic Reports at: http://www.marketresearchreports.com/therapeutic